What are the types of calcium channel blockers used in hypertension?

Types of Calcium Channel Blockers Used in Hypertension

Calcium channel blockers for hypertension are divided into two main classes: dihydropyridines (such as amlodipine, nifedipine, felodipine, nicardipine, and isradipine) and non-dihydropyridines (verapamil and diltiazem), with dihydropyridines being the preferred first-line CCBs for most hypertensive patients. 1, 2, 3

Classification and Mechanism

Dihydropyridine CCBs

These agents produce predominantly peripheral arterial vasodilation with minimal to no effects on AV conduction or sinus node function 1, 4:

• Amlodipine (5-10 mg once daily) - long-acting
• Nifedipine (slow-release: 30-180 mg daily) - avoid immediate-release formulations
• Felodipine (5-10 mg once daily) - long-acting
• Nicardipine (20-40 mg three times daily) - short-acting
• Isradipine (2.5-10 mg twice daily) - medium duration
• Nisoldipine (20-40 mg once daily) - short-acting

Non-Dihydropyridine CCBs

These agents have prominent effects on AV conduction and sinus node function in addition to peripheral vasodilation 1, 4:

• Diltiazem (immediate-release: 30-90 mg four times daily; slow-release: 120-360 mg once daily)
• Verapamil (immediate-release: 80-160 mg three times daily; slow-release: 120-480 mg once daily)

Clinical Selection Guidelines

The 2024 ESC and 2017 ACC/AHA guidelines recommend dihydropyridine CCBs as first-line agents for hypertension alongside ACE inhibitors, ARBs, and thiazide-like diuretics 2, 3. The choice between dihydropyridine and non-dihydropyridine depends on specific clinical scenarios:

Use Dihydropyridines When:

• Treating uncomplicated hypertension as first-line therapy 2, 3
• Patient has isolated systolic hypertension 5
• Combining with beta-blockers (safe combination) 1
• Patient has preserved left ventricular function 6

Use Non-Dihydropyridines When:

• Patient has concurrent angina requiring rate control 1, 7
• Vasospastic angina is present 7
• Patient has relative tachycardia at baseline (diltiazem preferred) 8

Critical Contraindications and Warnings

Avoid rapid-release, short-acting nifedipine unless used with concomitant beta-blockade due to increased adverse cardiovascular events 1, 4. This is a Class III recommendation (harmful).

Avoid verapamil and diltiazem in patients with:

• Pulmonary edema 1, 4
• Severe left ventricular dysfunction 1, 6
• Heart failure with reduced ejection fraction 6

The non-dihydropyridines can worsen heart failure due to their negative inotropic effects 6.

Combination Therapy Considerations

For stage 2 hypertension (≥140/90 mmHg), initiate with two-drug combinations, preferably as single-pill combinations 2. Preferred combinations include:

• CCB + ACE inhibitor or ARB (most effective combination) 9, 10
• CCB + thiazide diuretic 9, 3

Three-drug combination: CCB + thiazide + (ACE inhibitor or ARB) 9

Special Populations

Heart Failure Patients

• Amlodipine and felodipine are reasonably well-tolerated in mild LV dysfunction 1, 6
• Amlodipine showed safety in the PRAISE trial for severe HFrEF 6
• Non-dihydropyridines are contraindicated in HFrEF 6

Diabetes and CKD

• Dihydropyridine CCBs are recommended as first-line agents 11
• Newer L/T-type and L/N-type CCBs (lercanidipine, manidipine) may provide additional renoprotection in proteinuric CKD 12, 13

Common Pitfalls

1. Never use immediate-release nifedipine without beta-blocker coverage - associated with increased MI risk 1, 7
2. Don't prescribe non-dihydropyridines for heart failure - negative inotropic effects worsen outcomes 6
3. Peripheral edema is common with dihydropyridines - combining with ACE inhibitor/ARB reduces this side effect 14, 5
4. Monitor for hypotension, especially when combining with other antihypertensives 1